Catherine Meyers, M.D.
Director, Office of Clinical and Regulatory Affairs
Catherine Meyers, M.D., is the Director of NCCAM’s Office of Clinical and Regulatory Affairs. Dr. Meyers is responsible for planning, coordinating, and monitoring NCCAM’s clinical trials. She and her staff serve as a resource for NCCAM’s program staff and extramural clinical investigators to facilitate safe implementation of NCCAM-funded clinical studies. In addition, Dr. Meyers oversees NCCAM-appointed Data Safety Monitoring Boards and ensures regulatory compliance for NCCAM-initiated projects, including compliance with U.S. Food and Drug Administration (FDA) regulations.
Dr. Meyers earned her B.S. in Chemistry at the University of Chicago and received her M.D. from the University of Illinois at Chicago. She completed post-graduate residency training in internal medicine at the University of Chicago and a clinical nephrology fellowship at the University of Pennsylvania, Philadelphia, PA. She then completed a research nephrology fellowship in renal immunology at the University of Pennsylvania. Following her fellowship, she was a faculty member of the University of Pennsylvania’s School of Medicine for seven years, with an appointment in the Department of Internal Medicine, Renal-Electrolyte and Hypertension Division. In the laboratory, Dr. Meyers’ research focused on characterizing mechanisms of immune-mediated kidney injury.
A decade before her 2009 arrival at NCCAM, Dr. Meyers began a three-year tenure at the FDA where she provided oversight for trials of products for extracorporeal therapies as the Medical Officer at the Center for Devices and Radiological Health. Dr. Meyers joined the National Institutes of Health (NIH) in 2002 as a Senior Scientific Advisor within the National Institute of Diabetes and Digestive and Kidney Diseases. She also worked on several NIH projects, including the NIH Transplantation Research Coordinating Committee and was the co-chair of the NIDDK Clinical Studies Working Group.
Dr. Meyers’ research interests include autoimmune mechanisms of disease, chronic kidney disease, and hemodialysis vascular access inflammation. She is the recipient of many awards, including the FDA Honor Award for her work related to oversight of hemodialysis products and the NIDDK Director’s Award for her role in the development of the NIDDK Clinical Studies Working Group. She has over 90 publications and is a Fellow of the American Heart Association.